Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A non-invasive, multi-dimensional study of early detection of prostate cancer with urine

ABSTRACT: A non-invasive, multi-dimensional study of early detection of prostate cancer with urine

PROVIDER: PRJNA1183913 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A non-invasive, multi-dimensional study of early detection of prostate cancer with urine

Project description:A non-invasive, multi-dimensional study of early detection of prostate cancer with urine

| PRJNA1183914 | ENA

Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer

Project description:Objective was to identify urine cell-free microRNAs enabling early non-invasive detection of bladder cancer. Total RNA enriched for fraction of short RNAs was isolated using Urine microRNA purification kit (Norgen corp.). miRNA profiles were determined using the Affymetrix GeneChip miRNA 3.0 array and analyzed to identify differentially deregulated miRNA in bladder cancer patients compared with helathy controls.

2017-10-29 | E-MTAB-6102 | biostudies-arrayexpress

Identifying urinary RNA from prospective urine as non-invasive biomarkers for kidney transplant patients

Project description:To identify urinary RNA from prospective urine as non-invasive biomarkers for kidney transplant patients

2019-03-16 | GSE128347 | GEO

Identifying urinary RNA from biopsy associated urine as non-invasive biomarkers for kidney transplant patients

Project description:To identify urinary RNA from biopsy associated urine as non-invasive biomarkers for kidney transplant patients

2019-03-16 | GSE128348 | GEO

Screening of urine methylation biomarker for prostate cancer detection

Project description:Methylation profiling of urine samples from patients with aggressive prostate cancer and without prostate cancer. Methylated DNA was immunoprecipitated with anti-methylcytosine antibodies from genomic DNA and detected by Affymetrix CytoScanHD chips. Methylated DNA was purified by 5-mC antibodies and Affymetrix CytoScanHD arrays were performed according to the manufacturer's protocols.

2019-03-07 | E-MTAB-7732 | biostudies-arrayexpress

Identification of gene expression biomarkers in urine for the non-invasive detection of bladder cancer

Project description:Fifty patient urine samples diagnosed as high-grade urothelial carcinoma (HGUC) or benign were evaluated for bladder cancer via urine cytology. RNA was isolated and analyzed by microarray to identify a panel of biomarkers differentially expressed in HGUC and benign.

2018-04-17 | GSE68020 | GEO

Differentially Expressed Glycoproteins in Pre- and Post-Digital Rectal Examination Urine Samples for Detecting Aggressive Prostate Cancer

Project description:Nonaggressive prostate cancer (NAG-PCa) with Gleason score of 6 is considered as a low-risk disease and does not require clinical interventions. However, current assessment of aggressiveness of PCa is invasive using needle biopsies. Urine is an appealing biospecimen for noninvasive detection of aggressive PCa. Using urine, particularly from easily obtainable from pre-DRE urine specimens, to identify AG-PCa-associated molecular markers is critical for clinical risk stratification. Herein, we acquired quantitative mass spectrometry data for glycoproteins from pre-DRE and post-DRE urine specimens from patients underwent PCa diagnosis with biopsies. Compared with urinary glycoproteins identified from post-DRE urine samples, we confirmed that three previously reported AG-PCa-associated glycoproteins identified in post-DRE urine specimens were also found to be significantly associated with AG disease in pre-DRE urine samples. In addition, new AG-PCa-associated glycoproteins were identified in pre-DRE urine specimens. Our study provides a foundation for further studies of AG-PCa biomarkers using pre-DRE urine specimens.

2023-07-20 | PXD036468 | Pride

Detection of Aggressive Prostate Cancer-Associated Glycoproteins in Urine using Glycoproteomics and Mass Spectrometry

Project description:Clinical management of prostate cancer remains a significant challenge due to the lack of available tests for guiding treatment decisions. The blood Prostate-Specific Antigen (PSA) test has facilitated early detection and intervention of prostate cancer. However, blood PSA levels are less effective in distinguishing aggressive from indolent prostate cancers and other benign prostatic diseases. Thus, the development of novel approaches specific for prostate cancer that can differentiate aggressive from indolent disease remains an urgent medical need. In the current study, we evaluated urine specimens from prostate cancer patients instead of serum using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the aim of identifying effective prostate cancer biomarkers. Glycoproteins from urine samples of prostate cancer patients with different Gleason scores were characterized via solid phase extraction of N-linked glycosite-containing peptides and LC-MS/MS. In total, 2923 unique glycosite-containing peptides were identified. Comparison of urine-based glycoproteins with those identified from aggressive and non-aggressive prostate cancer tissues as well as sera from prostate cancer patients revealed that the majority of aggressive prostate cancer-associated glycoproteins were more readily detected in patient urine than serum samples. Our data collectively indicate that urine provides a highly reliable source for biomarker testing in patients with aggressive prostate cancer.

2022-02-28 | PXD004495 | Pride

Urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma (PDAC)

Project description:Currently, the majority of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) present with locally invasive and/or metastatic disease, resulting in five-year survival of less than 5%. The development of an early diagnostic test is, therefore, expected to significantly impact the patient’s prognosis. In this feasibility study, we demonstrate for the first time the utility of miRNA biomarkers for non-invasive, early detection of PDAC in urine specimens.

2016-01-28 | GSE71962 | GEO

Analysis of miRNA expression in urine of Hirschsprung's disease (HSCR) patients

Project description:Urine miRNA signature as potential non-invasive diagnostic biomarker for Hirschsprung’s Disease (HSCR): Unfortunately, HSCR diagnosis remains a challenge: current diagnostic methods are too invasive and difficult to conduct and to interpret. We designed this study in urine with the aim of identifying a non-invasive biomarker, which undoubtfully, would be a more convenient method for both babies and parents in the future.

2025-01-13 | GSE277874 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data